Comparison of the Use of Immune Checkpoint Inhibitor/Tyrosine Kinase Inhibitor and Tyrosine Kinase Inhibitor Alone for Patients With Low Risk Metastatic Renal Cell Carcinoma
Based on its superiority with respect to ORR and AE at our Institution, ICI/TKI therapy should be considered whenever possible, even in patients in the IMDC favourable risk group.
Authors
- YASUSHI MOCHIZUKI
- Kensuke Mitsunari (ORCID: https://orcid.org/0000-0002-6963-5632)
- RYOICHI IMAMURA
- Kojiro Ohba
- Tsuyoshi Matsuda (ORCID: https://orcid.org/0000-0001-8914-8236)
- Tomohiro Matsuo (ORCID: https://orcid.org/0000-0002-9508-0319)
- Hiromi Nakanishi (ORCID: https://orcid.org/0000-0001-5556-5058)
- Yuta Mukae
- Masaharu Oki
Institutions
- Nagasaki University Hospital (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2025-10-29
- DOI
- https://doi.org/10.21873/invivo.14142
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00